Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared on X:

“Our latest study, led by Ada Waks, now out on ACS Journal Cancer. Among ~13,000 patients with stage I HER2+ BC in SEER, those with tumors <1 cm had excellent survival (5y BCSS rate 97.6%–99.6%) irrespective of chemo receipt, whereas a 4% BCSS benefit with chemo was seen in pT1c.”

Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2‐positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010–2019 – Waks – 2025 – Cancer – Wiley Online Library

Authors: Adrienne G. Waks, Paolo Tarantino, Emily L. Chen, Rachel A. Freedman, Nancy U. Lin, Nabihah Tayob, Carlos T. Vallejo, Julieta Leone, Sara M. Tolaney, Jose Pablo Leone.

Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer